GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
PETALUMA, Calif., April 06, 2016 -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the receipt of several new U.S. and foreign patents relating to its Microcyn® Technology hypochlorous acid formulations. Specifically, the company has been granted a U.S. patent, as well as a Canadian patent, for the use of the Oculus Microcyn® Technology in the treatment of atopic dermatitis. In addition, two new patents in Mexico and Canada have recently been issued to Oculus relating to other hydrogel formulations and antimicrobial solutions.
Dr. Bob Northey, Oculus senior vice president for research and development said: “We continue to focus on the expansion of our intellectual property portfolio. Our Microcyn-based products are now commercialized in more than forty countries worldwide. The evidence documenting Microcyn’s efficacy and safety in the treatment of a broad spectrum of skin dermatoses is firmly aligned with our business strategy to increase Oculus’ penetration of the dermatology market, the core focus of our marketing and sales efforts.”
These newly issued patents expand Oculus' significant intellectual property portfolio (either owned or licensed to Oculus) that now includes 53 issued patents (12 in the United States and 41 foreign patents) as well as 70 pending patent applications (both U.S. and foreign) directed to compositions, apparatuses, methods of manufacturing and therapeutic uses.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “continue,” “aligned,” and “increase,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s common stock and warrants may be delisted from NASDAQ, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the year ended March 30, 2015. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Oculus® and Microcyn® Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact: Oculus Innovative Sciences, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 [email protected]
